ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,630Medicare Part D Prescriptions Filled, Including Refills

Rank: 29 out of 1300

$451K Total Retail Price of All Prescriptions

Rank: 42 out of 1300

621 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Colorado
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 621 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

7% of this provider’s 621 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 8,385 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Colorado
LEVOTHYROXINE SODIUM 575 516 1 1
SIMVASTATIN 526 469 2 3
LISINOPRIL 344 298 3 2
AMLODIPINE BESYLATE 279 241 4 6
OMEPRAZOLE 276 254 5 4
METOPROLOL TARTRATE 255 234 6 11
METFORMIN HCL 243 205 7 7
WARFARIN SODIUM 195 194 8 9
SERTRALINE HCL 192 177 9 26
FUROSEMIDE 190 189 10 8
ZOLPIDEM TARTRATE 186 152 11 14
HYDROCHLOROTHIAZIDE 180 165 12 10
HYDROCODONE-ACETAMINOPHEN 165 131 S3 13 5
TAMSULOSIN HCL 153 118 14 25
GABAPENTIN 142 136 15 15
POTASSIUM CHLORIDE 140 140 16 18
ALLOPURINOL 137 129 17 29
METOPROLOL SUCCINATE 132 132 18 24
LOVASTATIN 130 125 19 22
LISINOPRIL-HYDROCHLOROTHIAZIDE 130 116 19 21
DONEPEZIL HCL 128 127 21 32
FLUOXETINE HCL 102 78 22 31
ROPINIROLE HCL 88 77 23 106
ATENOLOL 86 82 24 12
ATORVASTATIN CALCIUM 83 74 25 13
CYMBALTA 82 65 26 44
PREDNISONE 78 65 27 40
FAMOTIDINE 77 77 28 73
LOSARTAN-HYDROCHLOROTHIAZIDE 76 76 29 78
TRAMADOL HCL 75 59 30 17
ADVAIR DISKUS 73 70 31 41
ALENDRONATE SODIUM 73 71 31 20
TRAZODONE HCL 72 50 33 34
PANTOPRAZOLE SODIUM 71 67 34 36
LOSARTAN POTASSIUM 67 65 35 16
PRAVASTATIN SODIUM 66 60 36 23
CITALOPRAM HBR 65 55 37 19
DIOVAN 65 59 37 66
TRIAMTERENE-HCTZ 63 63 39 54
OXYCODONE-ACETAMINOPHEN 61 38 S2 40 28
FLUTICASONE PROPIONATE 60 49 41 30
PAROXETINE HCL 55 52 42 59
CYCLOBENZAPRINE HCL 54 31 R 43 58
ESCITALOPRAM OXALATE 50 41 44 84
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 9, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.